Sofosbuvir/velpatasvir/voxilaprevir
(Redirected from Vosevi)
Combination of | |
---|---|
Sofosbuvir | NS5B RNA polymerase inhibitor |
Velpatasvir | NS5A inhibitor |
Voxilaprevir | NS3/4A protease inhibitor |
Clinical data | |
Trade names | Vosevi |
AHFS/Drugs.com | Monograph |
MedlinePlus | a617037 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth (tablets) |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C111H135F5N17O26PS |
Molar mass | 2281.42 g·mol−1 |
3D model (JSmol) | |
| |
|
Sofosbuvir/velpatasvir/voxilaprevir, sold under the brand name Vosevi, is a fixed-dose combination medication for the treatment of hepatitis C. It combines three drugs that each act by a different mechanism of action against the hepatitis C virus: sofosbuvir, velpatasvir, and voxilaprevir.[1]
Vosevi was approved for medical use in the United States and in the European Union in July 2017.[2][3] Vosevi is sold by Gilead Sciences.
References
- ^ Childs-Kean LM, Brumwell NA, Lodl EF (2019). "Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C". Infection and Drug Resistance. 12: 2259–2268. doi:10.2147/IDR.S171338. PMC 6662169. PMID 31413603.
- ^ "FDA approves Vosevi for Hepatitis C". U.S. Food and Drug Administration (FDA) (Press release). 18 July 2017. Archived from the original on 23 July 2017. Retrieved 27 July 2017.
- ^ "Vosevi EPAR". European Medicines Agency (EMA). Retrieved 24 September 2020.
External links
- "Sofosbuvir mixture with velpatasvir and voxilaprevir". Drug Information Portal. U.S. National Library of Medicine.
Categories:
- Use dmy dates from January 2020
- Drugs with non-standard legal status
- Pages using infobox drug with unknown parameters
- Infobox drug articles with contradicting parameter input
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Multiple chemicals in Infobox drug
- Multiple chemicals in an infobox that need indexing
- Chemical articles with multiple CAS registry numbers
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Combination drugs
- NS3/4A protease inhibitors
- NS5B (polymerase) inhibitors
- NS5A inhibitors
- All stub articles
- Antiinfective agent stubs